| Dr. B Abraham Pc | |
|
3020 Highway 124 Snellville GA 30039-4614 | |
| (770) 978-1331 | |
| (770) 978-8580 |
| Full Name | Dr. B Abraham Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 3020 Highway 124, Snellville, Georgia |
| Authorized Official Name and Position | Stephanie Leigh Mcdonald (OFFICE MANAGER) |
| Authorized Official Contact | 7709781331 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dr. B Abraham Pc 3020 Highway 124 Snellville GA 30039-4614 Ph: (770) 978-1331 | Dr. B Abraham Pc 3020 Highway 124 Snellville GA 30039-4614 Ph: (770) 978-1331 |
| NPI Number | 1104826775 |
|---|---|
| Provider Enumeration Date | 07/26/2005 |
| Last Update Date | 12/18/2012 |
| Medicare PECOS PAC ID | 4981693314 |
|---|---|
| Medicare Enrollment ID | O20040510001427 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104826775 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Benjamin Abraham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538156542 PECOS PAC ID: 6709830516 Enrollment ID: I20050307000033 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Provider Name | Nana Atta-asamoah |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1194920934 PECOS PAC ID: 0547449878 Enrollment ID: I20110119000588 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Provider Name | Todd Bender |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013360767 PECOS PAC ID: 7911257555 Enrollment ID: I20180901000095 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Provider Name | Kasey Lila Lieu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245716505 PECOS PAC ID: 6204189590 Enrollment ID: I20181103000056 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Provider Name | Bede Soon Tae Cha |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528427291 PECOS PAC ID: 0244596633 Enrollment ID: I20190624001411 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
| Provider Name | Gainneos R. Goldie |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1194778878 PECOS PAC ID: 3779515754 Enrollment ID: I20210305000359 |
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
News Archive
The Health Care Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. region of the UFIT noninvasive medical device created by Biosign Technologies Inc. of Canada, is pleased to announce that it has placed orders for delivery this quarter and will begin a limited release in March to those M.E.N.A. regions that recognize the CE Mark for medical device registration.
PINKconcussions and Georgetown University Medical Center, with support for the NCAA Sports Science Institute and US Lacrosse, are hosting the first summit to explore gender differences of female brain injuries including symptoms, treatment and recovery to develop a better model of care.
A new study led by Stony Brook University Cancer Center researchers to be published in Nature Communications suggests that the choice of anesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
Neural stem and progenitor cells, from the so-called subventricular zone, can help to repair a brain damaged by central nervous system disorders.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.
› Verified 7 days ago
Horizons Healthcare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2795 Main St W, #27, Snellville, GA 30078 Phone: 770-985-8001 | |
Rediclinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1550 Scenic Hwy N, Snellville, GA 30078 Phone: 866-607-7334 | |
Snellville Primary Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1800 Tree Ln, Ste 290a, Snellville, GA 30078 Phone: 770-979-1544 Fax: 770-979-5662 | |
John E. West, M.d., P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2295 Henry Clower Blvd, Suite 101, Snellville, GA 30078 Phone: 770-972-4871 Fax: 770-979-3782 | |
Fine & Associates Internal Medicine Specialists, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1561 Janmar Rd Ste E, Snellville, GA 30078 Phone: 770-736-8962 Fax: 770-736-8970 | |
Brookwood Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1550 Janmar Rd # B, Snellville, GA 30078 Phone: 770-979-9331 Fax: 770-979-8827 |